Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Bobby Berry who wrote (606)	11/11/1998 1:05:00 AM
From: ACC	Read Replies (1) \| Respond to of 975

axonal regeneration too? go2net.newsalert.com BOSTON--(BW HealthWire)--Nov. 10, 1998--Boston Life Sciences, Inc. (Nasdaq:BLSI)announced that its collaborating scientists have presented new findings concerning the regulation of axon growth in CNS nerve cell. These findings were presented on Nov. 8, 1998, at the annual meeting of the Society for Neuroscience by Dr. Larry Benowitz and colleagues from the Children's Memorial Hospital and Harvard Medical School in Boston. The findings have additionally just been published in the Journal of Biological Chemistry, vol. 273; pp. 29629-29634; 1998, the Company said. "We regard these findings as extremely important, since they describe for the first time the intracellular pathway that may control axon growth in all nerve cells. We believe BLSI has established a very promising proprietary position regarding therapeutic intervention in this pathway; one that includes the two lead nerve regeneration compounds that we are developing," stated Dr. Marc Lanser, Chief Scientific Officer at BLSI. "Subsequent research by our collaborating scientists in animals using one of BLSI's licensed compounds has not only reinforced the potential importance of this pathway in regenerating nerve cell axons, but also indicates that our compound has the apparent unique ability to regenerate axons in the functionally important pyramidal tracts that descend along the entire length of the spinal cord. Upon further confirmation of the preliminary anatomic findings, it would be, to our knowledge, the first time that any compound has been shown to cause substantial regeneration of axons in the pyramidal tract, which is absolutely vital for achievement of functional recovery in humans," added Dr. Lanser. "Given the importance of pyramidal tract regeneration, we believe that these results obtained in a highly recognized model demonstrate BLSI's leading role in the field of CNS nerve regeneration. However, only clinical trials can determine whether these preliminary anatomic results will translate into functional recovery in humans," stated David Hillson, President of BLSI. "This success has strengthened our commitment to the development of these compounds for spinal cord injury, stroke, and eventually chronic CNS degenerative diseases as well," added Hillson. ACC